Clinical trial NCT00810134: Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study
Official title: A Randomised Controlled Trial for the Treatment of 5 - 25 cm Superficial Femoral Artery oc-Clusions Comparing Femoropopliteal Bypass With 6 mm PTFE-Prosthesis and 6 - 7 mm Viabahn Endoprosthesis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Femoral Artery Occlusion
Keywords: Superficial femoral artery occlusion (TASC II B or C)
Lead sponsor: University of Helsinki
Sponsor class: OTHER
Collaborators: name: W.L.Gore & Associates
First posted: 2008-12-17
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare PTFE-graft bypass surgery versus Viabahn endoprosthesis for femoropopliteal arterial occlusion in intermittent claudication and critical ischaemia in patients who would be technically amenable for both treatments. The primary objective is to compare primary patencies of the two treatments. The secondary objective of the study is to evaluate secondary patency, functional status, the quality of life and costs of the new endovascular therapy.

Detailed description: Femoropopliteal bypass graft surgery with PTFE-prosthesis has proven to be an acceptable treatment for stable incapacitating claudication and critical ischaemia in patients with superficial femoral artery occlusion. Preliminary results of a thrupass endoprosthesis in the treatment of femoral lesions are promising. Less morbidity and better cost-effectiveness are suggested to be achieved in treatment of chronic lower limb ischaemia with endovascular treatment comparing to surgical treatment.

A randomised multicentre trial aims to enrol a pilot group of 60 + 60 patients to be followed for 3 years. Patients are treated either with Viabahn thrupass endoprosthesis (Gore corp.) or with 6 mm PTFE-prosthesis bypass graft surgery. Primary patency at three years is the primary end point and secondary patency, functional success, costs and quality of life are the secondary end points.

Eligibility criteria: Inclusion Criteria:

1. Superficial femoral artery occlusion from 5 to 25 cm in length above the knee joint.
2. Patient must be equally eligible for both procedures.
3. Patient must present intermittent claudication with resistance to medical therapy and exercise or critical ischaemia.
4. Normal adjacent vessel diameter must be between 4.8 and 6.5 mm.
5. At least one patent distal run-off vessel and at least 1 cm of healthy superficial femoral artery below and above the lesion to allow proper placement of the endoprosthesis.
6. Patient must be 18 years or older.
7. Women of childbearing age must have negative pregnancy test prior to inclusion.

Exclusion Criteria:

1. Known allergy or contraindications to aspirin, clopidogrel, dipyridamole or anticoagulants.
2. Bleeding diatheses
3. Presence of one or several previously placed endoprosthesis or grafts in the superficial femoral artery segment.
4. Planned other endovascular therapy of the same segment.
5. Other than 6-7 mm diameter endoprosthesis or 6 mm PTFE-prosthesis is needed.
6. Presence of evolving malignant cancer or any other illness posing an immediate threat to life.
7. Life-expectancy less than 2 years due to co-morbidity or other situation that would make the patient unlikely candidate for follow-up visits.
8. Participation in another vascular clinical study less than 30 days prior to inclusion.
9. Patients unable to fill out the prescribed quality of life questionnaires themselves or unable to understand the full meaning of the informed consent.

Primary outcomes:
measure: Primary end point of the study will be primary patency. Patency should be demonstrated by duplex ultrasound or other imaging modality at every control visit. ABI measurements will be recorded to assess the haemodynamic effect of the procedure.
timeFrame: At three years after intervention
Secondary outcomes:
measure: Suboptimal outcome is defined as the presence of any of the following: re-stenosis diagnosed by colour duplex ultrasonography, ankle-brachial index improvement of less than 0.15, or re-intervention at the treated site.
timeFrame: At any time of the study
measure: Secondary patency is defined by procedures required to re-establish or maintain blood flow after occlusion.
timeFrame: At any time of the study
measure: Complications will include post procedure haemorrhage, haematomas, cardiac, pulmonary and renal complications and infection. Technical problems or equipment failure in the endoprosthesis group will also be recorded.
timeFrame: At any time of the study
measure: A procedural death will be any death that will occur within 30 days of the procedure.
timeFrame: At any time of the study
measure: Immediate functional failure is one in which the threshold increase of ABI is not achieved within 24 hours. Early failure is any failure occurring within 30 days of the operation.
timeFrame: within 30 days of the operation
measure: Limb salvage is defined as retention of the leg without any major amputation or death.
timeFrame: At any time of the study
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Department of Vascular Surgery, Helsinki University Central Hospital
Study officials:
affiliation: Department of Vascular Surgery, Helsinki University Central Hospital
name: Mauri Lepantalo, M.D., PhD
role: PRINCIPAL_INVESTIGATOR
References: